ClinicalTrials.gg
Active, not recruitingNCT07266090Updated Jul 28, 2026

A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)

A Phase 2 interventional study of cenerimod 4 mg in SLE - Systemic Lupus Erythematosus, sponsored by Viatris Pharmaceuticals Co., Ltd.. Active, not recruiting at 7 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Viatris Pharmaceuticals Co., Ltd. (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
194th of 245
15 · median 36
Started
2026
with 55 others
Phase 2
33 of 266
14 open now
Primary completion
2027-10
later than 119 of 190 live
Registered
203rd of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 194th largest by planned enrollment of the 245 interventional ones that give a count, is one of 56 that started in 2026, is one of 33 in phase 2, reaches primary completion later than 119 of the 190 other live ones, and was the 203rd registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about the safety, how the body processes the drug, and its effects of a drug called cenerimod in adult Chinese participants (aged 18-75) with moderate to severe Systemic Lupus Erythematosus (SLE) who are already receiving standard background therapy.

The main questions it aims to answer are:

  • What is the safety and tolerability of a daily 4 mg dose of cenerimod in Chinese participants with SLE?
  • How is cenerimod processed by the body (pharmacokinetics) in this population?
  • What is the effect of cenerimod on the level of lymphocytes in the blood (pharmacodynamics)? This is a single-arm study without a comparison group.

Participants will:

  • Take one 4 mg cenerimod tablet by mouth once daily for up to 12 months.
  • Continue their stable, pre-existing background SLE medications throughout the study.
  • Attend regular clinic visits over a period of up to 22 months for tests and check-ups, including blood draws, heart monitoring (12-lead electrocardiogram), vital signs(blood pressure),and physical examinations.
  • Undergo a final safety follow-up 6 months after their last dose of the study drug.
03

Conditions studied

  • SLE - Systemic Lupus Erythematosus

Keywords

  • cenerimod
  • ACT-334441
  • safety
  • tolerability
  • pharmacokinetics
  • pharmacodynamics
  • Chinese participants
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated ICF prior to any study-mandated procedure.
  2. Male and female Chinese participants aged from 18 to 75 years old (inclusive) at the time of signing the ICF.
  3. Diagnosis of SLE made at least 6 months prior to Screening, according to 2019 European League Against Rheumatism / American College of Rheumatology Criteria.
  4. An mSLEDAI-2K score ≥ 6 and clinical mSLEDAI-2K score ≥ 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers).

    Note: The mSLEDAI-2K score does not include "leukopenia". The clinical mSLEDAI-2K is the mSLEDAI-2K assessment score without the inclusion of points attributable to hematuria, proteinuria, pyuria, urinary casts, low complement, increased DNA binding, and thrombocytopenia.

  5. PGA score ≥ 1.0 on a 0 to 3 VAS.
  6. Currently treated with one or more of the following SLE background medications:

    • Antimalarials: (≤ 400 mg/day hydroxychloroquine, ≤ 500 mg/day chloroquine, ≤ 100 mg/day quinacrine),
    • Mycophenolate mofetil (≤ 2 g/day) / mycophenolic acid (≤ 1.44 g/day),
    • Azathioprine (≤ 2 mg/kg/day),
    • Methotrexate (≤ 25 mg/week),
    • Oral (s) (OCS):

      • If OCS is the only SLE background medication:

        ≥ 7.5 mg/day and ≤ 30 mg/day prednisone or equivalent.

      • If OCS is not the only SLE background medication:

        • 30 mg/day prednisone or equivalent.
    • Belimumab (≤ 10 mg/kg every 4 weeks intravenously [i.v.] or ≤ 200 mg/week subcutaneously [s.c.]).
    • Telitacicept (≤ 240 mg/week subcutaneously). Treatment with antimalarials, mycophenolate mofetil, mycophenolic acid, azathioprine, methotrexate, belimumab, or telitacicept must have been started at least 90 days prior to Screening.

    Treatment with OCS must have been started at least 30 days prior to Screening.

  7. For women of (WoCBP):

    • Negative serum pregnancy test at Screening.
    • Agreement to undertake monthly urine pregnancy tests from Day 1 up to 6 months after study treatment discontinuation.
    • Agreement to use a highly effective method of from Screening (Visit 1) up to 6 months after study treatment discontinuation.
  8. On Day 1 before dosing,A clinical mSLEDAI-2K score ≥ 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers).
  9. On Day 1 before dosing,PGA score ≥ 1.0 on a 0 to 3 VAS.
  10. On Day 1 before dosing,Presence of at least one of the following biomarkers of serological evidence of active SLE (in a Screening sample as measured by central laboratory):

    • Anti-dsDNA antibodies elevated above normal.
    • Antinuclear antibodies (ANA) with a titer of at least 1:160.
    • Anti-Smith (anti-Sm) antibody elevated above normal.
  11. On Day 1 before dosing,Currently treated with one or more of the following SLE background medications that must be stable for at least 30 days prior to Day 1 (except OCS, which must be stable for at least 15 days prior to Day 1):

    • Antimalarials (≤ 400 mg/day hydroxychloroquine, ≤ 500 mg/day chloroquine, ≤ 100 mg/day quinacrine),
    • Mycophenolate mofetil (≤ 2 g/day) / mycophenolic acid (≤ 1.44 g/day),
    • Azathioprine (≤ 2 mg/kg/day),
    • Methotrexate (≤ 25 mg/week),
    • OCS:

      • If OCS is the only SLE background medication:

        • 7.5 mg/day and ≤ 30 mg/day prednisone or equivalent.
      • If OCS is not the only SLE background medication:

        • 30 mg/day prednisone or equivalent.
    • Belimumab (≤ 10 mg/kg every 4 weeks i.v. or

      ≤ 200 mg/week s.c.);

    • Telitacicept (≤ 240 mg/week subcutaneously).
  12. On Day 1 before dosing,WoCBP must have a negative urine pregnancy test.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant, planning to be become pregnant up to 6 months after the last dose of cenerimod in this study, or lactating women.
  2. Active severe SLE-driven renal disease (within 90 days prior to Screening or during Screening) where, in the judgment of the investigator, protocol-specified SLE background therapy is insufficient and the use of a more aggressive therapeutic approach or other treatments not permitted in the protocol is indicated.
  3. Urine protein/creatinine ratio> 3000 mg/g (i.e., > 339.45 mg/mmol) at Screening assessment based on central assessment.
  4. Severe active central nervous system lupus or active severe or unstable neuropsychiatric SLE including but not limited to: aseptic meningitis; cerebral vasculitis; myelopathy; demyelination syndromes (ascending, transverse, acute inflammatory demyelinating polyradiculopathy); acute confusional state; impaired level of consciousness; psychosis; acute stroke or stroke syndrome; cranial neuropathy; status epilepticus; cerebellar ataxia; or mononeuritis multiplex:

    • That would make the participant unable to fully understand the ICF. or
    • Where, in the opinion of the investigator/delegate, protocol-specified standard of care is insufficient and the use of a more aggressive therapeutic approach, such as adding i.v. cyclophosphamide and/or high dose i.v. pulse (CS) therapy or other treatments not permitted in the protocol is indicated.
  5. Severe forms of vasculitis (e.g., retinal vasculitis, coronary vasculitis, pulmonary vasculitis, mesenteric vasculitis) requiring systemic treatment within 90 days prior to Screening or during Screening.
  6. A diagnosis of mixed connective tissue disease or any history of overlap syndromes of SLE with psoriasis, rheumatoid arthritis, erosive arthritis, scleroderma, hepatitis, or uncontrolled autoimmune thyroid disease.
  7. History or presence of Mobitz type II or third-degree atrioventricular block, sick sinus syndrome, symptomatic bradycardia, or syncope associated with cardiac disorders.
  8. Participants who experienced myocardial infarction, unstable angina pectoris, stroke, , vascular thrombosis, decompensated heart failure requiring hospitalization, or heart failure defined by the Class III/IV (see Appendix 14) within 6 months prior to Screening.
  9. Resting HR \< 50 beats per minute as measured by the 12-lead at Screening or at Day 1 prior to study treatment administration.
  10. An elevated interval of > 470 ms (females) / > 450 ms (males) at Screening or at Day 1 prior to study treatment administration.
  11. History or presence of severe respiratory disease or pulmonary fibrosis, based on medical history, lung function, and chest X-ray (or CT scan as per local guidelines), performed at Screening or within 6 months prior to Screening.
  12. History of bronchial asthma or that has required treatment with oral or parenteral CS for more than a total of 2 weeks within the last 6 months prior to Screening.
  13. Have had household contact with a person with active Tuberculosis (TB) and did not receive appropriate and documented prophylaxis for TB.
  14. Have evidence of active TB or latent TB

    1. Active TB: Have evidence of active TB, defined in this study as the following:

      • Medical history, clinical features, and abnormal chest X- ray at Screening indicating the presence of TB.
      • IFN gamma release assay (IGRA): participants are excluded from the study if the test is not negative and there is clinical evidence of active TB.

      Exception 1: participants with a history of active TB who have documented evidence of appropriate treatment, have no history of re-exposure since their treatment was completed, have no clinical features of active TB, and have a Screening chest X-ray with no evidence of active TB may be enrolled if other entry criteria met. Such participants would not be required to undergo the IGRA test, but must have a chest X- ray at Screening (i.e., chest imaging performed within the past 6 months will not be accepted).

    2. Latent TB: Have evidence of untreated/inadequately or inappropriately treated latent TB, defined in this study as the following:

      • An IGRA test which is not negative, no clinical features consistent with active TB, and a chest X-ray with no evidence of active TB at Screening;
      • If the IGRA test results are positive, the participant will be considered to have latent TB. If the test is not negative, the test may be repeated once within approximately 2 weeks of the initial value. If the repeat test results are again not negative, the participant will be considered to have latent TB (for purposes of this study).

    Exception 2: participants with a history of latent TB who have documented evidence of appropriate treatment, have no history of re-exposure since their treatment was completed, have no clinical features of active TB, and have a Screening chest X-ray with no evidence of active TB may be enrolled if other entry criteria met. Such participants would not be required to undergo the IGRA test, but must have a chest X- ray at Screening (i.e., chest imaging performed within the past 6 months will not be accepted).

  15. Ongoing bacterial, viral, parasitic, or fungal infection that is of clinical concern according to the investigator or any of the following:

    • Clinically significant chronic infection (e.g., osteomyelitis, bronchiectasis, etc.) within 8 weeks prior to Screening (chronic nail infections are allowed).
    • Any infection requiring hospitalization or treatment with i.v. anti-infectives not completed at least 4 weeks prior to Screening.
  16. Positive results for serological markers for hepatitis A, B, C, and E indicating acute or chronic infection:

    • Anti-hepatitis A virus (HAV) immunoglobulin M (IgM).
    • surface antigen.
    • Anti- virus (HCV) IgG or IgM (if positive IgM and/or IgG, to be confirmed by HCV-RNA polymerase chain reaction assessment, and if this assessment is negative, participant can be enrolled).
    • Anti-hepatitis E virus (HEV) IgG or IgM (if positive IgM and/or IgG, to be confirmed by HEV-RNA polymerase chain reaction, and if this assessment is negative, participant can be enrolled).
  17. Participants who have congenital or acquired severe immunodeficiency or known (HIV) infection or positive HIV testing.
  18. Negative IgG antibody test for varicella-zoster virus.
  19. History or presence of (except for surgically excised and non-recurrent cutaneous basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma), lymphoproliferative disease, or history of total lymphoid irradiation within 10 years prior to Screening.
  20. History or presence of homologous (allogenic) bone marrow or solid organ transplantation.
  21. Presence of macular edema or active uveitis detected by optical coherence tomography (OCT) during Screening.
  22. Documented poorly controlled diabetes mellitus (i.e., > 8.0% at Screening as reported by the central laboratory or unstable blood sugar control/treatment adherence as per investigator's judgment) or diabetes mellitus complicated with organ involvement, such as diabetic nephropathy or retinopathy as assessed by investigator.
  23. History of chronic liver or biliary disease (other than Gilbert's Syndrome) or participants with or aspartate aminotransferase > 3 × or total > 1.5 ×upper limit of normal (unless in the context of known Gilbert's Syndrome).
  24. Significant hematology abnormality at screening assessment:

    • Lymphocyte count \< 500 /μL (0.5 × 10\^9/L);
    • \< 7 g/dL;
    • White blood cell count \< 2000/μL (2.0 × 10\^9/L) or
    • \< 25,000/μL (25 × 10\^9/L).
  25. Estimated \< 15 mL/min/1.73 m\^2.
  26. Treatment with the following medications within 15 days or 5 half-lives of the medication (whichever is longer) prior to Day 1:

    • β-blockers, diltiazem, verapamil, digoxin, digitoxin, or any other anti-arrhythmic or HR-lowering systemic therapy.
    • QT-prolonging drugs with known risk of torsade de pointes irrespective of indication.
  27. Treatment with the following medications within 30 days or 5 half-lives of the medication (whichever is longer) prior to Day 1:

    • Cyclophosphamide, cyclosporine, voclosporin, tacrolimus, sirolimus, etc.
    • Pulse methylprednisolone.
    • Vaccination with .
  28. Intra-articular, intramuscular or i.v. CS within 6 weeks prior to Day 1.
  29. Treatment with the following medications within 90 days or 5 half-lives of the medication (whichever is longer) prior to Day 1:

    • Leflunomide.
    • i.v. immunoglobulins.
  30. Treatment with any agent within 90 days or 5 half-lives of the drug (whichever is longer) prior to Day 1.
  31. Treatment with B cell-depleting biological agents (e.g., rituximab or ocrelizumab) or biological immunosuppressive agents (e.g., anti-tumor necrosis factor, anti-interleukin- [IL]1, anti-IL-6 therapies), within 12 months prior to Day 1.
  32. Treatment with anifrolumab within 6 months prior to Day 1.
  33. Treatment with any of the following medications any time prior to Screening:

    • Alemtuzumab.
    • Sphingosine-1-phosphate (S1P) receptor modulators (e.g., fingolimod).
    • Participants previously randomized to cenerimod or placebo in any trial involving cenerimod.
  34. Recent clinically significant drug or alcohol abuse as per investigator's judgment.
  35. Known allergy to S1P receptor modulators or any of the cenerimod formulation .
  36. Any other clinically relevant medical condition that would put the participant at risk if participating in the study, or any other diseases that may confound the disease activity assessments.
  37. Participants with body weight \< 40 kg at Screening or Day 1.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    cenerimod

    cenerimod 4 mg once daily

    Drug: cenerimod 4 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events (AEs)

    Treatment-emergent AEs are defined as any adverse event that occurs after the first dose of study treatment and up to 180 days after the last dose. This includes serious AEs (SAEs), AEs of special interest (AESIs), and AEs leading to permanent discontinuation of study treatment. AEs are coded using MedDRA and assessed by the investigator.

    Time frame: From first dose of study treatment up to 180 days after the last dose

  2. Occurrence of adverse events leading to permanent discontinuation of study treatment

    Number of participants who permanently discontinue study treatment due to adverse events.

    Time frame: From first dose of study treatment up to end of treatment,maximum duration of 12 months.

  3. Change from baseline in vital signs (systolic and diastolic blood pressure) and body weight

    Change in systolic blood pressure (SBP), diastolic blood pressure (DBP), and body weight from baseline to each post-baseline assessment. Measurements are performed in duplicate under standardized conditions.

    Time frame: Baseline, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8, Month 9, Month 10, Month 11, Month 12

  4. Change from baseline in 12-lead electrocardiogram (ECG) parameters

    Change in heart rate (HR), PR interval, QRS interval, QTcB interval, and QTcF interval from baseline to each post-baseline assessment.ECG abnormalities are assessed based on pre-defined criteria.

    Time frame: Baseline, Month 1, Month 2, Month 3, Month 4,Month 5,Month 6, Month 7, Month 8, Month 9, Month 10, Month 11, Month 12

  5. Change from baseline in laboratory parameters

    Change in hematology, blood chemistry, and urinalysis variables from baseline to each post-baseline assessment. Marked laboratory abnormalities are defined based on central laboratory reference ranges.

    Time frame: Baseline, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8, Month 9, Month 10, Month 11, Month 12

  6. Cenerimod Plasma Concentration

    Plasma concentrations of cenerimod are measured at multiple time points to characterize the pharmacokinetic profile. Concentrations are determined using a validated bioanalytical method (e.g., LC-MS/MS).

    Time frame: Pre-dose (0h), and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 hours post-dose on Day 1; Pre-dose on Day 30 (Month 1); Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 hours post-dose on Day 60 (Month 2); Pre-dose on Day 120 (Month 4); Pre-dose on Day 180

  7. Maximum plasma concentration (Cmax) of cenerimod

    Cmax is derived from plasma concentration-time profiles using non-compartmental analysis. Assessed during the first dosing interval on Day 1 and at steady state (Month 2).

    Time frame: Day 1 and Month 2

  8. Time to maximum plasma concentration (tmax) of cenerimod

    tmax is derived from plasma concentration-time profiles using non-compartmental analysis. Assessed during the first dosing interval on Day 1 and at steady state (Month 2). Time Frame: Day 1 and Month 2

    Time frame: Day 1 and Month 2

  9. Area under the plasma concentration-time curve from time zero to 24 hours (AUC0-24) of cenerimod

    AUC0-24 is derived during the first dosing interval on Day 1 using non-compartmental analysis.

    Time frame: Day 1

  10. Area under the plasma concentration-time curve over a dosing interval at steady state (AUCτ) of cenerimod

    AUCτ is derived at steady state (Month 2) using non-compartmental analysis.

    Time frame: Month 2

  11. Accumulation index (AI) of cenerimod

    AI is calculated as the ratio of AUC at steady state (Month 2) to AUC after the first dose (Day 1).

    Time frame: Between Day 1 and Month 2

  12. Change from baseline in total blood lymphocyte count

    Change in total blood lymphocyte count from baseline to each post-baseline assessment. This is a key pharmacodynamic marker for cenerimod.

    Time frame: Baseline to Month 12

  13. Number of participants with treatment-emergent medically relevant ECG abnormalities

    Treatment-emergent medically relevant ECG abnormalities are defined as new or worsening abnormalities from baseline to each post-baseline assessment, as determined by central reading.

    Time frame: Baseline to Month 12

  14. Number of participants with treatment-emergent marked laboratory abnormalities

    Treatment-emergent marked laboratory abnormalities are defined as new or worsening abnormalities in hematology, blood chemistry, or urinalysis from baseline to each post-baseline assessment, based on central laboratory criteria.

    Time frame: Baseline to Month 12

Other outcomes

  1. Proportion of participants achieving Systemic Lupus Erythematosus Responder Index 4 (SRI-4) response

    SRI-4 response is defined as a reduction of ≥4 points in mSLEDAI-2K score, no new BILAG A organ domain score, no more than 1 new BILAG B organ domain score, and no worsening in Physician's Global Assessment (PGA) score (assessed on a 0-3 VAS).

    Time frame: Baseline to Month 12

  2. Proportion of participants achieving response on modified Systemic Lupus Erythematosus Disease Activity Index 2000 (mSLEDAI-2K)

    Response is defined as a reduction in mSLEDAI-2K score from baseline. The mSLEDAI-2K assesses SLE disease activity without including "leukopenia" or laboratory items.

    Time frame: Baseline to Month 12

  3. Proportion of participants achieving British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response

    BICLA response is defined as improvement in all organ systems (reduction of all BILAG A scores to B/C/D and all B scores to C/D) with no worsening in other systems.

    Time frame: Baseline to Month 12

  4. Proportion of participants achieving response on Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)

    CLASI response is defined as improvement in skin activity score. CLASI assesses cutaneous lupus manifestations.

    Time frame: Baseline to Month 12

  5. Change from baseline in tender joint count

    Change in the number of tender joints from baseline to Month 12. Assessed by physical examination.

    Time frame: Baseline to Month 12

  6. Change from baseline in oral corticosteroid (OCS) dosage

    Change in the dose of OCS (prednisone or equivalent) from baseline to Month 12. OCS dosage is managed per protocol-specified rules.

    Time frame: Baseline to Month 12

07

Study locations

7 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Oct 2027, 20 months after the start.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's planned 20 months is below that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 5, 2025
StartActual
Jan 14, 2026
Primary completionEst.
Oct 8, 2027
CompletionEst.
Oct 8, 2027
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07266090
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Jan 14, 2026
Primary completion
Oct 8, 2027 (estimated)
Completion
Oct 8, 2027 (estimated)
Last update
Jul 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cenerimod

Start the discussion